From AML & MDS toevery blood cancer
We solved the hardest classification problem first. Now the same AI extraction + deterministic logic framework scales across all of haematology.
Leukaemia & Myeloid
2/7 completeAcute Myeloid Leukaemia
WHO 2022 & ICC 2022 dual-framework classification with ELN 2022/2024 risk stratification and clinical trial matching.
- WHO 2022 Classification
- ICC 2022 Classification
- ELN 2022 + 2024 Risk
- Clinical Trial Matching
Myelodysplastic Syndromes
Full WHO 2022 & ICC 2022 classification with IPSS-R risk scoring and morphology integration.
- WHO 2022 Classification
- ICC 2022 Classification
- IPSS-R Scoring
- Morphology Integration
Chronic Lymphocytic Leukaemia
B-cell chronic leukaemia with iwCLL staging, prognostic markers, and genetic risk stratification.
- iwCLL Staging
- Prognostic Markers
- Treatment Response
- Genetic Risk Factors
Acute Lymphoblastic Leukaemia
Paediatric and adult ALL classification with risk stratification and MRD monitoring.
- Paediatric ALL
- Adult ALL
- Genetic Subtypes
- MRD Monitoring
Chronic Myelomonocytic Leukaemia
MDS/MPN overlap neoplasm with CPSS scoring and transformation risk.
- WHO Classification
- CPSS Scoring
- Molecular Markers
- Transformation Risk
Chronic Myeloid Leukaemia
BCR-ABL positive leukaemia with phase classification and response monitoring.
- Phase Classification
- BCR-ABL Monitoring
- Resistance Mutations
- Treatment Response
Hairy Cell Leukaemia
Rare B-cell leukaemia with BRAF V600E detection and variant classification.
- Classic HCL
- HCL Variant
- BRAF V600E
- Treatment Response
Lymphoma
0/8 completeDiffuse Large B-Cell Lymphoma
Aggressive B-cell lymphoma with COO classification and double/triple hit detection.
- COO Classification
- Double/Triple Hit
- IPI Scoring
- Molecular Subtypes
Follicular Lymphoma
Indolent B-cell lymphoma with histologic grading and FLIPI risk assessment.
- Histologic Grading
- FLIPI Scoring
- Transformation Risk
- Molecular Markers
Hodgkin Lymphoma
Classical and nodular lymphocyte-predominant Hodgkin lymphoma with staging.
- Classical HL
- NLPHL
- Ann Arbor Staging
- Response Assessment
Mantle Cell Lymphoma
Aggressive B-cell lymphoma with MIPI scoring and TP53 status.
- Morphologic Variants
- MIPI Scoring
- TP53 Status
- Minimal Residual Disease
Marginal Zone Lymphomas
MALT, nodal, and splenic marginal zone lymphomas.
- MALT Lymphoma
- Nodal MZL
- Splenic MZL
- Site-specific Features
Burkitt Lymphoma
Highly aggressive B-cell lymphoma with MYC rearrangement confirmation.
- Endemic/Sporadic/Immunodeficiency
- MYC Rearrangements
- Morphologic Features
- Differential Diagnosis
Peripheral T-Cell Lymphomas
Heterogeneous group of mature T-cell neoplasms including ALCL.
- PTCL-NOS
- Angioimmunoblastic
- ALCL
- NK/T-cell Lymphomas
Cutaneous Lymphomas
Primary cutaneous B-cell and T-cell lymphomas including Mycosis Fungoides.
- Mycosis Fungoides
- Sezary Syndrome
- Primary Cutaneous DLBCL
- Staging Systems
Other Haematological
0/5 completePlasma Cell Disorders
Multiple myeloma, MGUS, and related plasma cell neoplasms with ISS staging.
- Multiple Myeloma
- MGUS Classification
- ISS Staging
- Prognostic Markers
Myeloproliferative Neoplasms
BCR-ABL negative MPNs — polycythaemia vera, essential thrombocythaemia, primary myelofibrosis.
- Polycythaemia Vera
- Essential Thrombocythaemia
- Primary Myelofibrosis
- JAK2/CALR/MPL
Mastocytosis
Clonal mast cell disorders with KIT D816V mutation detection.
- Cutaneous Mastocytosis
- Systemic Mastocytosis
- KIT D816V
- Prognostic Scoring
Bone Marrow Failure Syndromes
Aplastic anaemia and inherited bone marrow failure syndromes.
- Aplastic Anaemia
- Fanconi Anaemia
- Dyskeratosis Congenita
- Telomere Disorders
Histiocytic Disorders
Langerhans cell histiocytosis and Erdheim-Chester disease.
- Langerhans Cell Histiocytosis
- Erdheim-Chester Disease
- Haemophagocytic Lymphohistiocytosis
- BRAF/MAP2K1 Mutations